Pharmafile Logo
Pharmafocus logo
Advanced Search

Brilique

Showing 10 posts of 10 posts found.

astrazeneca_building_white

Thousands to benefit with new anti-clotting drug recommendation, says NICE

August 12, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor

The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …

News
EU flag

Three AstraZeneca drugs recommended by EMA committee

December 21, 2015
Sales and Marketing AstraZeneca, Brilique, CHMP, EMA, Portrazza, Tagrisoo, lesinurad, lilly

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended several new drugs in its latest meeting, including …

News
Brilique picture

Brilique recommended for use by Germany’s pricing watchdog

December 19, 2011
Sales and Marketing AstraZeneca, Brilique, Plavix

Germany’s new pricing committee has said that AstraZeneca’s Brilique is a cost effective treatment for patients with a certain heart …

News
Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature

Brilique gains NICE approval

October 31, 2011
Sales and Marketing ACS, Brilique, NICE, Plavix, clopidogrel

AstraZeneca’s Brilique has been approved by NICE for use in combination with aspirin as an option to treat patients with …

News
AZ's Brilinta (ticagrelor)

FDA approves AstraZeneca’s Brilinta after delay

July 21, 2011
Sales and Marketing AstraZeneca, Brilinta, Brilique, antiplatelet

The FDA has finally approved AstraZeneca’s oral blood thinner Brilinta after asking for more information on the drug last year.  …

News
AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor)

FDA delays approval of AstraZeneca’s Brilinta

December 20, 2010
Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome

US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …

News

AZ’s Brilique approved in Europe

December 7, 2010
Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor

European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …

News

AZ plans heart attack study for Brilique

October 8, 2010
Research and Development, Sales and Marketing AstraZeneca, Brilinta, Brilique

AstraZeneca is due to begin enrolling patients into a new study of its oral antiplatelet Brilique (ticagrelor) before the end …

News

AZ’s antiplatelet recommended for European approval

September 27, 2010
Sales and Marketing Brilinta, Brilique, Brillinta, Possia

AstraZeneca’s oral antiplatelet treatment Brilique has received a positive opinion from a key European advisory committee. A marketing authorisation for …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026